Regeneron CEO on 23andMe & $275m in Margaritaville 6/11/25
The U.S. and China have reached a framework for a trade deal, marking progress in the London talks between both nations. Bankrupt 23andMe is up for sale, and drugmaker Regeneron is at the negotiating table. CEO Dr. Len Schleifer discusses the value of genetic data in medicine, explaining the role DNA plays in developing drug therapies. Plus, Elon Musk has posted an X of regret after publicly clashing with President Trump on social media, and CNBC’s Robert Frank reports on Jimmy Buffett’s $275 million estate, currently caught between the Margaritaville empire’s two trustees. Dr. Len Schleifer - 14:18 Robert Frank - 29:14 In this episode: Robert Frank, @robtfrank Becky Quick, @BeckyQuick Joe Kernen, @JoeSquawk Katie Kramer, @Kramer_Katie
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
The U.S. and China have reached a framework for a trade deal, marking progress in the London talks between both nations. Bankrupt23andMe is up for sale, and drugmaker Regeneron is at the negotiating table. CEO Dr. Len Schleifer discusses the value of genetic data in medicine, explaining the role DNA plays in developing drug therapies. Plus, Elon Musk has posted an X of regret after publicly clashing with President Trump on social media, and CNBC’s Robert Frank reports on Jimmy Buffett’s $275 million estate, currently caught between the Margaritaville empire’s two trustees.
Dr. Len Schleifer - 14:18
Robert Frank - 29:14
In this episode:
Robert Frank, @robtfrank
Becky Quick, @BeckyQuick
Joe Kernen, @JoeSquawk
Katie Kramer, @Kramer_Katie
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.